Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout flare

Tocilizumab Designated as Breakthrough Therapy for GCA

Michele B. Kaufman, PharmD, BCGP  |  October 26, 2016

To speed the development of tocilizumab to treat giant cell arteritis (GCA), the FDA designated it as a breakthrough therapy earlier this month…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:FDAFood and Drug AdministrationGiant Cell Arteritisgiant cell arteritis (GCA)Gouthyperuricemialesinuradtocilizumab

The Patient's Choice

When Rheumatologists Are a Patient’s Second or Third Choice for Medical Opinion

Charles Radis, DO  |  September 7, 2016

Outside Exam Room No. 5, the chart rack was empty, so I assumed my new consult was late. Just in case, I looked back over my shoulder as I passed by the partially open door and glimpsed the lower half of a woman holding a three-ringed binder on her lap. I squinted and took a…

Filed under:ConditionsPractice SupportPsoriatic Arthritis Tagged with:ArthritisLyme Diseasepatient carePractice ManagementPsoriatic ArthritisRheumatic Diseaserheumatologist

Rheumatology Coding Corner Questions: ICD-10 Coding Guidelines, Conventions Refresher Quiz Part 2

From the College  |  February 17, 2016

A patient returns for a follow-up visit of their chronic idiopathic gout without tophi with complaints of pain and tenderness. After a thorough examination, the rheumatologist treats the patient for an acute flare of the left knee. How is this coded? M1A.1620, M10.062 M1A.1620 M10.061 M10.062 From ICD-10 coding guidelines, what are the steps to…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisPractice Support Tagged with:BillingCodingGoutguidelineICD-10ObesityPainRheumatoid arthritisrheumatology

Rheumatology Coding Corner Answers: ICD-10 Coding Guidelines, Conventions Refresher Quiz Part 2

From the College  |  February 17, 2016

Take the challenge. D—Even though the patient’s chief complaint is for a follow-up of chronic idiopathic gout without tophi, the patient is presenting with an acute flare of idiopathic gout of the left knee. Acute gout and chronic gout have specific coding guidelines, because they each have an Excludes 1 note. This indicates they are…

Filed under:Billing/CodingConditionsFrom the CollegeGout and Crystalline ArthritisPractice Support Tagged with:BillingCodingGoutguidelineICD-10ObesityPainRheumatoid arthritisrheumatology

2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges

Thomas R. Collins  |  February 16, 2016

SAN FRANCISCO—Behçet’s disease is a vasculitis that can be hard to pin down, with a wide variety of manifestations, many of which overlap with other auto-inflammatory conditions, an expert said at a clinical review course at the 2015 ACR/ARHP Annual Meeting. The most common feature is oral ulcers, which are expected to be seen at…

Filed under:ConditionsMeeting ReportsResearch RheumVasculitis Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Behçet’s diseaseDiagnosisoral ulcerpatient careResearchTreatmentVasculitis

FDA Approves New Drugs for Pain

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2016

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsFDAOsteoarthritisPainrheumatologySafety

Rheumatologist Steven S. Overman Reflects on His Last Day of Practice, Future of Specialty

Steven S. Overman, MD, MPH • illustrations by Alice C. Gray  |  November 16, 2015

I am a few weeks post-retirement. Having written thank you notes and completed urgent home projects, I swing in a hammock at our currently fire-threatened cabin north of Winthrop, Wash., and reflect. I feel like a young boy while freely flipping pages of a hand-scribed picture book, The Principles of Uncertainty, by Maira Kalman. She…

Filed under:Practice SupportProfiles Tagged with:Profileretirementrheumatologistrheumatology practice

Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do

Jennifer Stichman, MD, and Dennis J. Boyle, MD  |  April 1, 2015

Lack of efficacy, poor DAS scores may be misinterpreted as a drug failure

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:adherenceBoyleMedicationpatient carerheumatology

2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News

Michele B. Kaufman, PharmD, BCGP  |  January 1, 2015

Plus, hydrocodone combination products and brodalumab

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline ArthritisMeeting Reports Tagged with:2014 ACR/ARHP Annual MeetingbrodalumabFDAhydrocodoneKaufmanrheumatologySafety

Cryopyrin-Associated Periodic Syndromes: Difficult to Recognize, Diagnose, Treat

Philip J. Hashkes, MD, MSc, & Ronald M. Laxer, MDCM, FRCPC  |  October 1, 2014

Two case studies demonstrate the difficulty, delay in recognizing this rare autoinflammatory disease

Filed under:Career DevelopmentConditionsEducation & TrainingOther Rheumatic ConditionsProfessional TopicsResearch Rheum Tagged with:autoinflammatoryCAPSClinicalDiagnosispatient careResearchrheumatologistSteroidsTreatment

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences